United States · Safety & cost
Compounded vs generic vs brand-name GLP-1s in the US
Applies to: United States
By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due January 31, 2027
Clinical review: not yet reviewed by a clinician. How review works · Editorial policy
"Compounded," "generic" and "brand-name" are often used as if they meant the same thing. In the US they don't: the FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold[1].
The three kinds of product
| Item | FDA-approved? | What it means |
|---|---|---|
| Brand-name (e.g. Wegovy, Zepbound) | Yes | Has an FDA label setting out its uses, doses and warnings |
| Compounded | No | Not reviewed by the FDA for safety, effectiveness or quality before sale |
| Sold as “generic” but compounded | No | The FDA says the word implies sameness with an approved product |
Why compounding was allowed, and what changed
Compounders were given temporary flexibility while semaglutide and tirzepatide were on the FDA's shortage list. The FDA declared the tirzepatide injection shortage resolved on October 2, 2024 (reaffirmed December 19, 2024) and the semaglutide injection shortage resolved on February 21, 2025[2].
The FDA then ended its enforcement discretion in stages through spring 2025: for tirzepatide, March 10 (state-licensed pharmacies, section 503A) and March 19 (outsourcing facilities, 503B); for semaglutide, April 2025 (503A) and May 22 (503B). Courts denied compounders' requests to block these decisions[2].
What the FDA warns about
The FDA says it knows of no lawful basis for compounding with salt forms such as semaglutide sodium or semaglutide acetate, and warns that counterfeit GLP-1 products may contain the wrong ingredients or too much, too little or none of the active ingredient[1].
Lower-cost approved routes
For published self-pay and savings routes for approved products, see cost without insurance and savings cards, explained.
General information, not medical or legal advice. Light Years does not link to or earn from any seller of any product named here.
Have a quote from your own pharmacy? Work out your monthly and yearly cost — it runs in your browser, and nothing you type is sent anywhere.
Sources
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed November 2, 2026. Back to the text
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize. Accessed November 2, 2026. Back to the text
- Warning letter 715866 (compounded semaglutide marketing), September 9, 2025. U.S. Food and Drug Administration, September 9, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/semabio-715866-09092025. Accessed November 2, 2026. Back to the text
- WEGOVY (semaglutide) injection and WEGOVY tablets — prescribing information. U.S. Food and Drug Administration (FDALabel), June 2026. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ee06186f-2aa3-4990-a760-757579d8f77b/spl-doc. Accessed November 2, 2026. Back to the text
Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.
Changes to this page
- — First published.
Substantive corrections are also logged at corrections.